MX389586B - Composicion farmaceutica que comprende un betabloqueante, un inhibidor de la enzima de conversion y un antihipertensivo o un aine - Google Patents

Composicion farmaceutica que comprende un betabloqueante, un inhibidor de la enzima de conversion y un antihipertensivo o un aine

Info

Publication number
MX389586B
MX389586B MX2018012790A MX2018012790A MX389586B MX 389586 B MX389586 B MX 389586B MX 2018012790 A MX2018012790 A MX 2018012790A MX 2018012790 A MX2018012790 A MX 2018012790A MX 389586 B MX389586 B MX 389586B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
antihypertensive
nsaid
converting enzyme
enzyme inhibitor
Prior art date
Application number
MX2018012790A
Other languages
English (en)
Spanish (es)
Inventor
Gilles Fonknechten
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX389586B publication Critical patent/MX389586B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2018012790A 2016-04-20 2017-04-19 Composicion farmaceutica que comprende un betabloqueante, un inhibidor de la enzima de conversion y un antihipertensivo o un aine MX389586B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1653502A FR3050380B1 (fr) 2016-04-20 2016-04-20 Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains.
PCT/FR2017/050929 WO2017182754A1 (fr) 2016-04-20 2017-04-19 Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains

Publications (1)

Publication Number Publication Date
MX389586B true MX389586B (es) 2025-03-20

Family

ID=56943614

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012790A MX389586B (es) 2016-04-20 2017-04-19 Composicion farmaceutica que comprende un betabloqueante, un inhibidor de la enzima de conversion y un antihipertensivo o un aine

Country Status (15)

Country Link
EP (1) EP3445342A1 (fr)
KR (1) KR102267965B1 (fr)
CN (1) CN109069438A (fr)
BR (1) BR112018070968A2 (fr)
EA (1) EA201892354A1 (fr)
FR (1) FR3050380B1 (fr)
GE (2) GEP20217310B (fr)
MA (1) MA44728A (fr)
MX (1) MX389586B (fr)
PH (1) PH12018502155B1 (fr)
RU (1) RU2756320C2 (fr)
SG (2) SG11201808848SA (fr)
TN (1) TN2018000344A1 (fr)
UA (1) UA125511C2 (fr)
WO (1) WO2017182754A1 (fr)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2645710C2 (de) 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
FR2503155A2 (fr) 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2620709B1 (fr) 1987-09-17 1990-09-07 Adir Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese
FR2807431B1 (fr) 2000-04-06 2002-07-19 Adir Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
AR036187A1 (es) 2001-07-24 2004-08-18 Adir Un proceso para la preparacion de perindopril, compuestos analogos y sus sales, compuesto intermediario 2,5-dioxo-oxazolidina y proceso para preparar un intermediario
FR2827860B1 (fr) 2001-07-24 2004-12-10 Servier Lab Nouveau procede de synthese de derives de l'acide (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxyline et application a la synthese du perindopril
ATE365714T1 (de) 2002-01-30 2007-07-15 Servier Lab Verfahren zur herstellung von hochreinem perindopril und zwischenverbindungen nützlich in der synthese
FR2838648B1 (fr) 2002-04-18 2004-05-21 Servier Lab Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
ATE395913T1 (de) 2003-02-28 2008-06-15 Servier S A Lab Verfahren zur herstellung von perindopril
DE60301930T2 (de) 2003-02-28 2006-07-27 Les Laboratoires Servier Verfahren für die Synthese von Perindopril und seiner pharmazeutisch annehmbaren Salze
PT1321471E (pt) 2003-03-12 2005-07-29 Servier Lab Novo processo de sintese do perindopril e dos seus sais aceitaveis sob o ponto de vista farmaceutico
SI1367061T1 (sl) 2003-06-30 2006-04-30 Servier Lab Nov postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli
SI1362864T1 (sl) 2003-06-30 2007-08-31 Servier Lab Nov postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli
EP1648422A4 (fr) * 2003-07-28 2007-09-19 Reddys Lab Inc Dr Traitement et prevention d'accidents cardiovasculaires
DK1367062T3 (da) 2003-07-31 2007-01-02 Servier Lab Ny fremgangsmåde til syntese af perindopril og farmaceutisk acceptable salte heraf
ES2271498T3 (es) 2003-07-31 2007-04-16 Les Laboratoires Servier Nuevo procedimiento de sintesis de perindopril y de sus sales farmaceuticamente aceptables.
EP1380591B1 (fr) 2003-08-29 2005-11-16 Les Laboratoires Servier Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
ES2250853T3 (es) 2003-08-29 2006-04-16 Les Laboratoires Servier Procedimiento para la sintesis de perindopril y de sus sales farmaceuticamente aceptables.
DE60308102T2 (de) 2003-08-29 2007-06-21 Les Laboratoires Servier Verfahren für die Synthese von Perindopril und seiner pharmazeutisch annehmbaren Salzen
DE60311942T2 (de) 2003-11-19 2007-12-06 Les Laboratoires Servier Verfahren für die Synthese von Perindopril und seiner pharmazeutischen annehmbaren Salzen
EP1422236B1 (fr) 2003-11-19 2007-02-14 Les Laboratoires Servier Procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
SI1420029T1 (sl) 2003-12-10 2008-08-31 Servier Lab Postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli
SI21800A (sl) 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek sinteze perindoprila
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
FR2894825B1 (fr) 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2897866B1 (fr) 2006-02-28 2008-04-18 Servier Lab Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2897865B1 (fr) 2006-02-28 2008-04-18 Servier Lab Forme cristalline beta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CN101024082A (zh) * 2007-04-06 2007-08-29 张士东 一种全面预防和治疗心脑血管疾病复方药及其应用
AU2009263737B2 (en) 2008-06-24 2013-10-24 Tianish Laboratories Private Limited Novel polymorphic forms of Perindopril (L)-Arginine and process for the preparation thereof
HU230877B1 (hu) 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
US9789187B2 (en) * 2009-02-11 2017-10-17 Cadila Pharmaceuticals Limited Stable pharmaceutical composition for atherosclerosis
EP2424509A4 (fr) * 2009-04-30 2012-11-07 Reddys Lab Ltd Dr Formulations de combinaison de médicament à dose fixe
FR2961105B1 (fr) 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
FR2985511B1 (fr) 2012-01-05 2014-01-03 Servier Lab Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
SG11201808848SA (en) 2018-11-29
RU2018140193A3 (fr) 2020-06-03
PH12018502155B1 (en) 2024-03-27
PH12018502155A1 (en) 2019-07-15
FR3050380B1 (fr) 2020-07-10
FR3050380A1 (fr) 2017-10-27
MA44728A (fr) 2019-02-27
KR102267965B1 (ko) 2021-06-21
WO2017182754A1 (fr) 2017-10-26
GEAP202114923A (en) 2021-07-12
RU2018140193A (ru) 2020-05-20
KR20180132911A (ko) 2018-12-12
UA125511C2 (uk) 2022-04-13
TN2018000344A1 (en) 2020-06-15
EA201892354A1 (ru) 2019-04-30
BR112018070968A2 (pt) 2019-01-29
RU2756320C2 (ru) 2021-09-29
CN109069438A (zh) 2018-12-21
EP3445342A1 (fr) 2019-02-27
SG10202009894PA (en) 2020-11-27
GEP20217310B (en) 2021-11-10

Similar Documents

Publication Publication Date Title
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
JOP20200230B1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
BR112021021826A2 (pt) Terapias de combinação compreendendo os inibidores de apremilast e tyk2
MX2019009717A (es) Composicion farmaceutica.
EA202091533A1 (ru) Способы лечения диабета, гепатита и/или воспалительного заболевания печени
EP4585213A3 (fr) Formulations d'amlodipine
PH12020550532A1 (en) Agent for preventing or treating small intestinal injury induced by non-steroidal anti-inflammatory drug and proton pump inhibitor
AR112217A1 (es) Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CY1123322T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα μπισοπρολολη και περινδροπριλη
UY39504A (es) Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
MX389586B (es) Composicion farmaceutica que comprende un betabloqueante, un inhibidor de la enzima de conversion y un antihipertensivo o un aine
MX2019013970A (es) Composiciones farmaceuticas de liberacion sostenida retardada.
CO2019005207A2 (es) Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabética
MX2020003554A (es) Moduladores de la expresion de enac.
NI202000017A (es) Composición farmacéutica para la prevención o el tratamiento de enfermedades cardiovasculares acompañadas por diabetes, que incluye amlodipino, losartán y rosuvastatina, y preparación compuesta que incluye los mismos
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
Ardhianto et al. PM231 Factor Xa Levels In Atrial Fibrillation Secondary To Mitral Stenosis
BR112021015795A8 (pt) Composição
UA130472U (uk) Спосіб проведення діагностичної ангіографії
TR201914037A2 (tr) Alantolacton etken maddesi̇ni̇n multi̇ple sklerozi̇s hastaliğinda i̇laç adayi olarak kullanilmasi